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The use of the Xenopus model system has provided diverse contributions to cancer
research, not least because of the striking parallels between tumour pathogenesis
and early embryo development. Cell cycle regulation, signalling pathways, and cell
behaviours such as migration are frequently perturbed in cancers; all have been
investigated using Xenopus, and these developmental events can additionally act as
an assay for drug development studies. In this mini-review, we focus our discussion
primarily on whole embryo Xenopus models informing cancer biology; the contributions
to date and future potential. Insights into tumour immunity, oncogene function, and
visualisation of vascular responses during tumour formation have all been achieved with
naturally occurring tumours and induced-tumour-like-structures in Xenopus. Finally, as
we are now entering the era of genetically modified Xenopus models, we can harness
genome editing techniques to recapitulate human disease through creating embryos
with analogous genetic abnormalities. With the speed, versatility and accessibility that
epitomise the Xenopus system, this new range of pre-clinical Xenopus models has great
potential to advance our mechanistic understanding of oncogenesis and provide an
early in vivo model for chemotherapeutic development.
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INTRODUCTION
Cancer is a prominent cause of death worldwide and numbers of cases are predicted to increase as
populations grow and age (Torre et al., 2016). Oncology research is also expanding in parallel and
a wealth of discoveries have provided insight from a social level to intricate details of molecular
pathogenesis. These advances would not be possible without the use of research models, but
there is increasing pressure to reduce the use of mammalian animals in biomedical research, and
there is still a gap for relevant translational models for high-throughput screening for therapeutic
development (Naert et al., 2017). The articles in this special issue are testament to the versatility
of the Xenopus system, and in keeping, the full repertoire of in vitro biochemistry, oocytes,
explants, embryos, and adult frogs have all provided diverse contributions to cancer research,
from understanding biological processes that are deranged in cancer to modelling using a new
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age of genetically engineered transgenic animals. Here, we
summarise the breadth of Xenopus’ contribution to cancer
research (see also Hardwick and Philpott, 2015), focusing our
discussion on the development and application of whole embryos
and adult Xenopus frogs as in vivo models informing cancer
biology.
PARALLELS BETWEEN DEVELOPMENT
AND DISEASE
The wide-ranging application of Xenopus to the field of oncology
is built on the striking parallels between tumour pathogenesis
and early embryo development. The “hallmarks of cancer” are
now widely recognised as abnormal and tumorigenic properties
(Hanahan and Weinberg, 2000, 2011), yet they often arise
from inappropriate re-activation or de-regulation of normal
physiological processes, many of which are instrumental to
embryogenesis when precisely executed in space and time (Aiello
and Stanger, 2016). Considerable literature now documents the
similarities between early development and tumorigenesis in
terms of gene expression, proteasome, signalling pathways, and
cell behaviours (Ma et al., 2010). A greater understanding of the
physiological processes in the embryo, both in terms of molecular
components and regulatory mechanisms, may therefore give
insight into tumour pathogenesis and potential therapeutic
targets, as illustrated below.
To summarise the diverse application of the Xenopus system
to cancer research, Figure 1 illustrates contributions made
to understanding each of the cancer hallmarks. This includes
the use of in vitro extract systems, oocytes and developing
Xenopus embryos to study fundamental aspects of cell biology
such as DNA replication (Blow and Laskey, 2016), genome
maintenance (Hoogenboom et al., 2017), DNA damage response
(Cupello et al., 2016), cell cycle control (Philpott and Yew,
2008), metabolism (Ureta et al., 2001), and signalling pathways
(Hill, 2001; Kuhl, 2002; Smith et al., 2008; Pera et al., 2014).
Natural tumour immunity in amphibians has also elucidated
immune system interactions (Banach and Robert, 2017), and
together with in vitro experiments using extracts (Deming
and Kornbluth, 2006), morphogenesis of embryos provides a
physiological setting for study of apoptosis (Ishizuya-Oka, 2011;
Ito et al., 2012). Similarly, key stromal interactions during
tumour growth and metastasis have been informed by intra-
vital imaging in Xenopus tadpoles (Haynes-Gimore et al., 2015)
and by the study of developmental epithelial-to-mesenchymal
transition (EMT) events (Pegoraro and Monsoro-Burq, 2013)
that are key to malignant tumour invasion (Tanaka et al., 2016).
Finally, tadpoles and adult frogs contribute to our understanding
of genetic influences on tumorigenesis through induced-tumour-
like-structures (ITLSs) (Wallingford, 1999) and the use of a
new era of genetically engineered Xenopus models (GEXM)
(Naert et al., 2017).
Increasingly oncologists have harnessed and applied aspects
of the developmental biology toolbox, for example utilising
lineage tracing technologies to investigate tumour cell origin
and evolution (Aiello and Stanger, 2016). Similarly, given
that developmental and oncogenic processes often depend on
the same underlying pathways, it is perhaps not surprising
that embryonic events provide an in vivo assay system for
discovery and development of new therapeutics targeting these
pathways. For example, aberrant Wnt signalling can contribute
to all stages of tumorigenesis with a particularly prominent
driving role in intestinal cancers, yet it has proved difficult to
target therapeutically (Krishnamurthy and Kurzrock, 2018). Axis
duplication can be induced in Xenopus embryos by injection
of RNA encoding β-catenin into a ventral cell of a four cell
embryo (Kuhl and Pandur, 2008), and preventing this Wnt-
dependent secondary axis is a rapid and efficient screen for
potential Wnt inhibitors (Waaler et al., 2011; De Robertis
et al., 2013). Furthermore, monitoring developmental events
such as tadpole blood and lymphatic formation can be used
to screen chemical libraries for anti-angiogenic activity (Kalin
et al., 2009), and a transgenic Xenopus reporter model now
exists with expression of GFP in both blood and lymphatic
vasculature under the xFlk1 promoter (Ny et al., 2005, 2013)
simplifying such analysis even further. Additionally, gastrulation
and neural crest migration critically require transient EMT
events, and inhibition of the associated cell movements provides
an initial in vivo assay to identify compounds that may also
inhibit invasion and proliferation of several types of cancer
(Tanaka et al., 2016). The large numbers, accessibility and
rapid and robust development of embryos have earned Xenopus
worldwide credibility in developmental biology; these same
attributes are now valid for novel pharmacological screening
approaches and are likely be utilised further in the future
(Schmitt et al., 2014).
NATURALLY OCCURRING XENOPUS
TUMOURS AND ANTI-CANCER
DEFENCES
Naturally occurring tumours in Xenopus are believed to be rare,
and potent carcinogens known in mammals have limited ability
to induce tumours in amphibians, proving an intriguing insight
into mechanisms of relative resistance and/or altered sensitivity
to carcinogens. These may include control mechanisms present
that regulate adult tissue regeneration, altered self-tolerance post-
metamorphosis resulting in cancer cell rejection, ready induction
of apoptosis and a reduced sensitivity to DNA damage; reviewed
in Ruben et al. (2007). Amphibian skin also secretes a vast array
of antibiotic peptides but some of these have inhibitory activity
against human cancer cell growth, fuelling interest in defining
more of these natural peptide secretions (Li et al., 2016).
Mechanisms of Tumour Immunity
Inflammation and evading the immune system are two hallmarks
of cancer (Hanahan and Weinberg, 2011), and immune-
based therapy is already employed in both human (Zhang
and Chen, 2018) and veterinary cancer patients (Klingemann,
2018). However, a complex array of tumour and immune cell
interactions can have disparate effects, leading to the concept
of “immune-editing” of a heterogenous mix of tumour clones
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FIGURE 1 | Using the full Xenopus repertoire to inform on the hallmarks of cancer. Ten hallmarks of cancer are recognised (left) and Xenopus studies have informed
on each of these aspects (right) as described in the main text. Where possible review papers are referenced to direct readers to further discussion of each topic.
ITLSs, induced-tumour-like-structures; GEXM, genetically engineered Xenopus models.
(Bui and Schreiber, 2007). While some clones may be completely
destroyed by the host immune system, selection pressure can
create the persistence of clones with anti-immune defences
or reduced immunogenicity, promoting tumour growth (Bui
and Schreiber, 2007). Components of the innate and adaptive
immune systems are highly conserved between Xenopus and
mammals; readers are directed to Banach and Robert (2017) for
a recent and in-depth review. With the derivation of defined
immunogenic Xenopus cancer cell lines (see below), together with
in-bred MHC-defined strains of Xenopus that permit tumour
grafts without rejection, Xenopus is a highly valuable model
for dissecting the roles of various immune system components;
comprehensively reviewed in Goyos and Robert (2009); Robert
(2010), and Banach and Robert (2017).
Original reports of highly malignant lymphosarcoma in
Xenopus were subsequently demonstrated to be an infectious
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granuloma in response to mycobacterium marinum (Asfari,
1988; Asfari and Thiebaud, 1988), but a range of genuine
neoplastic and sometimes metastatic diseases are documented,
including hepatoma, teratoma, renal carcinoma, fibrosarcoma,
ovarian dysgerminoma, lymphoma, and pancreatic carcinoma
(Banach and Robert, 2017). In the 1990s, five thymic lymphomas
were reported in genetically different adult frogs, and these
have provided five different and now extensively characterised
lymphoid cell lines (B3B7, 15/0, 15/40, ff-2, and ff-2.64)
(Robert and Cohen, 1998). Features such as high levels of
myc expression, aneuploidy and genetic instability indicate
their relevance to mammalian cancers, and mixed expression
of T and B cell markers indicates resemblance to rare
human leukocytic leukaemias (Robert and Cohen, 1998). These
different thymic tumour cell lines arise in differing MHC
immune backgrounds and display differing behaviours and
invasiveness on transplantation, dependent on the immune
status of the recipient tadpole or adult (Robert et al., 1994).
These transplantation experiments coupled with the ease of
genetic manipulation in Xenopus have allowed dissection
of the mechanisms behind tumour and immune system
interactions, including a key role of adult T cells for defence
(Robert et al., 1997), and tumour expression of non-classical
MHC class1b molecules for escaping immune recognition
(Haynes-Gilmore et al., 2014).
Recent Advances Using Natural Tumour
Grafts
Transplantation studies using the aggressive 15/0 tumour
cell line and MHC compatible LG6 and LG15 tadpoles
have also led to the recent development of a semi-solid
tumour model by embedding tumour cells in a collagen
matrix prior to subcutaneous engrafting (Haynes-Gimore
et al., 2015). By fluorescently labelling tumour cells and
infusing intra-cardiac labelled dextran, neoangiogenesis is
visualised by intra-vital imaging to reveal a network of
convoluted tumour vessels with slow laminar blood flow,
recapitulating features of mammalian tumour vasculature.
Utilising the natural transparency of Xenopus tadpoles, the
semi-solid nature of the graft also enables visualisation
of collagen rearrangements and infiltrating melanophores,
characterising in real-time the tumour interaction with stroma
and immune components (Haynes-Gimore et al., 2015). Just
as developmental angiogenesis or neural crest formation
can provide an in vivo screen for inhibitory drugs (see
above), this accessible and well-characterised tumour model
will surely attract further attention for chemotherapeutic
development.
INDUCED TUMOUR-LIKE-STRUCTURES
(ITLS) AS EARLY XENOPUS MODELS OF
CANCER
Whilst there has been limited success in inducing tumours
in Xenopus by carcinogens, simple genetic manipulation by
RNA injection has been a cornerstone of the Xenopus system
to study key developmental proteins, and this approach has
also yielded early tumour models allowing characterisation
of the role of various oncogenes or tumour suppressor
proteins. These cancer models further emphasise the closely
entwined features of both development and cancer, with
developmental factors having influence on tumorigenesis,
and the discovery that known oncogenic proteins may
originally have a physiological role in development (Wallingford,
1999).
Developmental Regulators Influencing
Oncogenesis
One of the first tumour phenotypes in Xenopus was reported
through the study of tumour suppressor protein p53 in
normal embryo development (Wallingford et al., 1997).
Observations in tissue culture experiments and mouse models
have long demonstrated the oncogenic effects of mutant
p53, in part arising through a loss of cell cycle control and
genomic instability. To investigate its role in embryogenesis
and tumorigenesis, researchers turned to Xenopus where the
rapid development of embryos allows analysis without the
complicating effects of de novo mutations from inherent
genomic instability. Human p53 alterations are the most
common genetic abnormality in human cancers, often due
to dominant-negative effects, and the human protein is
biochemically similar to the Xenopus homolog, making
Xenopus a relevant oncological model (Wallingford, 1999).
Accordingly, targeted over-expression of dominant-negative
human p53 in Xenopus embryos inhibits differentiation
in multiple germ layers and produces cellular masses of
undifferentiated cells with abnormal nuclear morphologies
(Wallingford et al., 1997). This essential role of p53 in normal
differentiation, beyond its roles in cell cycle control, is now
well-documented in aspects of neurogenesis (Hardwick et al.,
2014) and supports the notion that certain cancers may arise
from a failure of differentiation rather than overt proliferation
defects per se; a concept also suggested using a Xenopus
developmental model for paediatric cancer Neuroblastoma
(Wylie et al., 2015).
Oncogenic Regulators Influencing
Development
Oncogenes can often directly influence aspects of cell fate
and development. For example, over-expression of the
viral oncogene polyoma middle T in Xenopus animal cap
explants results in re-specification of prospective ectoderm
to mesoderm, suggesting common signal transduction
pathways between early inductive signals and oncogenic
stimuli (Whitman and Melton, 1989). This is also supported
by investigations in Xenopus using dominant inhibitory
ras mutants, revealing a role for proto-oncogene p21ras in
transduction of FGF and activin signalling in mesoderm
induction (Whitman and Melton, 1992). Additionally, the Rel
family of transcriptional activators are a diverse group including
oncoprotein c-Rel. The Xenopus homolog Xrel3 is a distinct
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rel protein expressed in two phases of early development, and
its over-expression induces tumour formation (Yang et al.,
1998). It his highly plausible that a protein with a physiological
role in regulating the balance between cell proliferation and
differentiation may become subverted and contribute to
cancer formation, or alternatively there may be a convergence
of oncogenic stimuli on the same developmental signalling
pathways.
Characterising Oncogenes With Induced
Tumour Models
Consistent with this theme of aberrant use of signalling
pathways in oncogenesis, a Xenopus model of human basal
cell carcinoma (BCC) has revealed the importance of Gli1
as a target and mediator of sonic hedgehog (Shh) signalling
in BCC development. Over-expression of Gli1 in Xenopus
embryos results in focal epidermal lesions with marker
expression resembling that of human BCC and highlighting
Gli1 as a potential early biomarker for diagnosis of BCC
(Dahmane et al., 1997). Thus, ITLSs have been produced by
over-expression of a range of proteins relevant to human
cancers, and these tumours demonstrate disorganised
and undifferentiated cells, high mitotic indicies, stromal
interactions and neovascularisation (Chernet and Levin,
2013).
These same Xenopus models have also been used to
extensively explore membrane depolarisation as a bioelectric
marker predictive of ITLS foci (Chernet and Levin, 2013).
Transmembrane potential itself may be an oncogenic
driver and depolarisation of native neural crest cells
can non-cell autonomously induce neoplastic changes in
surrounding melanocytes (Blackiston et al., 2011; Lobikin
et al., 2012). Similarly, formation of ITLS can be suppressed by
hyperpolarisation of tumour or surrounding cells, suggested to
be mediated through enhanced tumour uptake of butyrate
with HDAC inhibitory properties, resulting in reduced
cellular proliferation (Chernet and Levin, 2013, 2014). For
further discussion (see Levin et al., 2017; Silver and Nelson,
2018).
GENETICALLY ENGINEERED XENOPUS
MODELS (GEXM)
From the preceding discussion, Xenopus models have already
assisted with investigation of both cancer pathogenesis and
therapeutic development. These models are being expanded to
a new dimension by using genome editing technology with
TALENs or CRISPR/Cas9; methodology discussed in Naert
et al. (2017). Genetically engineered mouse models are well-
established in the Oncology toolbox, but aquatic models like
zebrafish and Xenopus offer extra-uterine development of large
embryos and simple injection set-ups for delivery of targeted
nucleases, also usually lacking inherent complications of highly
inbred genetic backgrounds (Naert et al., 2017). In addition
to rapid development, high embryo number, and detailed fate
maps for tissue-specific targeting, Xenopus also presents several
advantages over zebrafish, such as reduced evolutionary distance
to humans. Moreover, Xenopus tropicalis has a true diploid
genome with substantial shared synteny with the human genome;
in zebrafish whole genome duplication leads to redundancy
and complications identifying human orthologs (Naert et al.,
2017).
The first GEXM was established to phenocopy Familial
Adenomatous Polyposis (FAP) by TALEN-mediated targeting
of the apc gene in Xenopus tropicalis, replicating the human
frame-shifting mutations and complementing models such as
the Apcmin mouse and ENU-induced apc zebrafish mutant (Van
Nieuwenhuysen et al., 2015). FAP is an autosomal dominant
disease due to truncating mutations of the apc gene, resulting in
100s to 1000s of adenomatous polyps in the colon, potentially
progressing to adenocarcinoma and sometimes accompanied
by extra-colonic manifestations. Although F0 tadpoles do not
develop genuine intestinal adenomas, they do display abnormal
histological architecture of the intestine and the lack of adenomas
may be explained by the distinct Xenopus intestinal folding
pattern that allows proliferating cells to spread rather than
form polyps (Van Nieuwenhuysen et al., 2015). Additionally,
retinal hyperplasia and external tumours such as subcutaneous
desmoid tumours resemble extra-colonic disease reported in
humans, each displaying increased Wnt signalling and only
mutant apc alleles. Thus, the Xenopus apc model provides high
penetrance and rapid and reproducible tumour formation that
is comparable to the human disease (Van Nieuwenhuysen et al.,
2015).
A second model by the same group used CRISPR/Cas9-
mediated knockout of rb1 and rbl1 genes in Xenopus tropicalis
to phenocopy Retinoblastoma, a paediatric tumour of the
developing retina (Naert et al., 2016). While mouse models
exist, they show variable latency to tumour development
and rely on conditional deletion as complete knock-out is
embryonic lethal, while a zebrafish model relies on orthotopic
retinoblastoma transplantation. As in mice, Xenopus tumours
require inactivation of both rb1 and rbl1 genes, achieved by
co-injection of independent pairs of guide RNAs and editing
by CRISPR-Cas9; these mosaic double knock-out tadpoles
develop a rapid and penetrant retinoblastoma in as little as
35 days, with histopathology and disease progression conserved
with the human tumour (Naert et al., 2016). Efficiency of
genome editing is reported at 25–30% for each locus, thus
neoplasias develop in F0 mosaic mutants without high genome
editing efficiencies, and given that an entire experiment can be
conducted within 3 months, this technology using the Xenopus
system has huge potential for future application (Naert et al.,
2016).
FUTURE PERSPECTIVES
Building on the extensive history of Xenopus in exploring
fundamental cell and developmental biology, we are now entering
a new era where modern genome editing technology is being
combined with all the classical attributes of the Xenopus system
to generate clinically relevant cancer models that are rapid,
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penetrant and highly suited to high-throughput screening. This is
an important step allowing reduction of the number of mammals
in pre-clinical research, and provides a range of platforms for
therapeutic development, either using developmental events to
screen for drugs targeting the same signalling pathways or
as relevant in vivo tumour models. Furthermore, the aquatic
nature of Xenopus permits fast and efficient preclinical screening
of water-soluble compounds (Naert et al., 2017). There is
also potential for characterising disease modifying genes by
multiplexed biallelic targeting in Xenopus and proof of principle
is already shown for dual target genes with TALENs (Naert et al.,
2017) and triplex gene editing with CRISPR (Naert et al., 2016).
Next steps will involve deletion of large chromosomal regions or
replicating chromosomal translocations and relocations (Naert
et al., 2017). Thus, Xenopus has rightfully earned a place in
the Oncologist’s toolbox and is likely to achieve even more
prominence as the unique advantages of the Xenopus system
become widely acknowledged in the oncology field.
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